Peter Greenleaf
Director at Altimmune, Inc. (ALT) since November 2026
Peter Greenleaf has filed 22 insider reports with the SEC since May 2021, as director at Altimmune, Inc. (ALT), director at Pelthos Therapeutics Inc. (PTHS) and chief Executive Officer at Aurinia Pharmaceuticals Inc. (AUPH) and at 2 more companies. In the last 12 months Peter Greenleaf sold $37.5K of stock on the open market. The latest filing, on November 4, 2026, reports grant or award at Altimmune, Inc. (ALT).
- Filings
- 22
- Companies
- 5
- Bought on market
- $54.9K
- Sold on market
- $4.02M
Companies where Peter Greenleaf is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince November 2026 | $1.645 | Nov 4, 2026 | |||||
| Directorsince July 2025 | 23,884 | $37.5K | $7.44 | Jul 7, 2026 | |||
| Chief Executive Officer | 1,840,379 | $54.9K | $3.98M | $10.71 | $15.73+47% | May 11, 2026 | |
| Director | 0 | May 26, 2022 | |||||
| Director | 0 | Mar 22, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Nov 2, 2026ALTDirector Greenleaf Peter was granted 160,000 stock optionsForm 4Grant or award
- Nov 2, 2026ALTPeter Greenleaf became an insiderForm 3New insider
- Jul 2, 2026-$20.8KPTHSDirector Greenleaf Peter sold $20,827 worth of shares (797 units at $26.13) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 23,884 units to satisfy withholding taxForm 4Open-market sale10b5-1 plan
- May 11, 2026~$49.7MAUPHPeter Greenleaf plans to sell 3,136,201 shares (~$49.7M)Form 144Planned sale
- Apr 2, 2026-$16.7KPTHSSEC Form 4 filed by Greenleaf PeterForm 4Open-market sale10b5-1 plan
- Jul 2, 2025PTHSAmendment: SEC Form 4 filed by Greenleaf PeterForm 4Grant or award
- Mar 2, 2026AUPHChief Executive Officer Greenleaf Peter was granted 196,403 shares and covered exercise/tax liability with 100,890 shares, increasing direct ownership by 5% to 1,840,379 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Feb 20, 2026AUPHChief Executive Officer Greenleaf Peter covered exercise/tax liability with 100,171 shares, decreasing direct ownership by 5% to 1,744,866 unitsForm 4Shares withheld for taxes or exercise price
- Jan 2, 2026AUPHChief Executive Officer Greenleaf Peter was granted 165,384 shares and covered exercise/tax liability with 113,169 shares, increasing direct ownership by 3% to 1,845,037 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Jul 2, 2025PTHSSEC Form 4 filed by Director Greenleaf PeterForm 4Grant or award
- Jul 1, 2025PTHSPeter Greenleaf became an insiderForm 3New insider
- Mar 4, 2025-$2.87MAUPHChief Executive Officer Greenleaf Peter was granted 624,433 shares and sold $2,871,124 worth of shares (360,540 units at $7.96), increasing direct ownership by 17% to 1,788,945 unitsForm 4Grant or awardOpen-market sale
- Mar 6, 2024-$711KAUPHGreenleaf Peter sold $711,094 worth of shares (126,981 units at $5.60), decreasing direct ownership by 8% to 1,522,114 unitsForm 4Open-market sale
- Feb 20, 2024AUPHGreenleaf Peter was granted 661,538 shares, increasing direct ownership by 67% to 1,649,095 unitsForm 4Grant or award
- Mar 2, 2023-$290KAUPHGreenleaf Peter sold $290,153 worth of shares (33,047 units at $8.78), decreasing direct ownership by 3% to 982,671 units (Amendment)Form 4Open-market sale
- May 24, 2022ATRSSEC Form 4: Greenleaf Peter returned $446,012 worth of shares to the company (79,645 units at $5.60), closing all direct ownership in the companyForm 4Sale back to the company
- Mar 22, 2022BDSISEC Form 4: Greenleaf Peter disposed of 105,034 shares, closing all direct ownership in the company to cover withholding taxForm 4Sale back to the companyOther acquisition or disposition
- Mar 2, 2022-$109KAUPHSEC Form 4: Greenleaf Peter was granted 28,300 shares and sold $108,907 worth of shares (9,068 units at $12.01), increasing direct ownership by 140% to 32,967 units to satisfy tax liabilityForm 4Grant or awardOpen-market sale
- Jan 27, 2022BDSISEC Form 4: Greenleaf Peter converted options into 10,246 shares, increasing direct ownership by 11% to 105,034 unitsForm 4Grant or awardExercise or conversion of a derivative
- Aug 6, 2021BDSISEC Form 4: Greenleaf Peter converted options into 35,000 units of Common Stock, increasing direct ownership by 59% to 94,788 unitsForm 4Exercise or conversion of a derivative
- Jun 10, 2021ATRSSEC Form 4: Greenleaf Peter was granted 25,452 units of Common Stock, increasing direct ownership by 47% to 79,645 unitsForm 4Grant or award
- May 11, 2021+$54.9KAUPHSEC Form 4: Greenleaf Peter bought $54,891 worth of Common Stock (5,125 units at $10.71), increasing direct ownership by 62% to 13,453 unitsForm 4Open-market purchase
Also sits on boards with
Officers and directors who share two or more companies with Peter Greenleaf.
- Todd C Davis2 shared: PTHS, BDSI
- Jeffrey Allen Bailey2 shared: AUPH, BDSI
- Scott M. Plesha2 shared: PTHS, BDSI
- Karen L. Smith2 shared: AUPH, ATRS
Compare Peter Greenleaf with
- Peter Greenleaf vs Todd C Davis2 shared
- Peter Greenleaf vs Jeffrey Allen Bailey2 shared
- Peter Greenleaf vs Scott M. Plesha2 shared
- Peter Greenleaf vs Karen L. Smith2 shared
- Peter Greenleaf vs Gregory L Weaver1 shared
- Peter Greenleaf vs Wayne Pisano1 shared
Other insiders at the same companies
- Gregory L WeaverALT
- Wayne PisanoALT
- Jerome Benedict DursoALT
- Alex G. HowarthALT
- Richard Thomas MenziusoALT
- Linda M RichardsonALT
- Stephen P. RobertsonAUPH
- M Scot RobertsALT
- Ezra M FriedbergPTHS
- Matthew PaulsPTHS
- Craig A JohnsonAUPH
- Kathleen GoetzAUPH
- Tina Susan NovaAUPH
- Kevin TangAUPH
Questions about Peter Greenleaf
- What is Peter Greenleaf's role at Altimmune, Inc.?
- Peter Greenleaf reports to the SEC as director at Altimmune, Inc. (ALT), according to the latest filing on November 4, 2026. Peter Greenleaf has also filed as director at Pelthos Therapeutics Inc. (PTHS), chief Executive Officer at Aurinia Pharmaceuticals Inc. (AUPH), director at Antares Pharma, Inc. (ATRS) and director at Biodelivery Sciences International Inc (BDSI).
- How many shares does Peter Greenleaf own?
- After the latest filing that states it, Peter Greenleaf directly owned 23,884 shares of Pelthos Therapeutics Inc. (PTHS) and 1,840,379 shares of Aurinia Pharmaceuticals Inc. (AUPH). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Peter Greenleaf bought or sold stock recently?
- The most recent open-market purchase was on May 11, 2021: bought 5,125 shares of Aurinia Pharmaceuticals Inc. (AUPH) for $54.9K at an average of $10.71. The most recent open-market sale was on July 2, 2026: sold 797 shares of Pelthos Therapeutics Inc. (PTHS) for $20.8K at an average of $26.13.
- How do I get alerts when Peter Greenleaf files?
- Follow Peter Greenleaf on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Peter Greenleaf filed 2 times in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Peter Greenleaf (SEC CIK 0001363683). Totals count each trade once, skipping amendments whose original is on file, from May 12, 2021 on. View on SEC EDGAR